Group A (n = 92) (omeprazole plus trimebutine) | Group B (n = 56) (omeprazole) | Significance (p) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

Prior | After 3 months | Prior | After 3 months | A v B | A1b v B1b | A2 v B2 | ||||||||

A1 (n = 73) | A2 (n = 19) | A1a (n = 12) | A1b (n = 61) | A2 (n = 19) | B1 (n = 45) | B2 (n = 11) | B1a (n = 8) | B1b (n = 37) | B2 (n = 11) | Prior | After | After | After | |

p values between the two groups were calculated using the χ^{2} test with Yates’ correction (two tailed p values). | ||||||||||||||

Group A, patients were assigned to three months of omeprazole plus trimebutine treatment; group B, patients were assigned to three months of omeprazole monotherapy; groups A1, B1, H pylori positive patients prior to treatment assigned to omeprazole plus trimebutine or omeprazole alone, respectively; groups A1a, B1a, patients from groups A1 and B1, respectively, who remained H pylori positive after the eradication regimen; groups A1b, B1b, patients from groups A1 and B1, respectively, in whom H pylori infection was eradicated; groups A2, B2, H pylori negative patients prior to and after treatment with omeprazole plus trimebutine or omeprazole alone, respectively | ||||||||||||||

GORD symptoms | 73 | 19 | 5 | 10 | 3 | 45 | 11 | 4 | 18 | 7 | NS | <0.001 | <0.005 | <0.025 |

Oesophagitis | 51 | 12 | 5 | 10 | 3 | 29 | 7 | 2 | 16 | 5 | NS | <0.01 | <0.01 | NS |

IBS symptoms | 73 | 19 | 2 | 7 | 3 | 45 | 11 | 4 | 23 | 7 | NS | <0.001 | <0.001 | <0.025 |